A recent study suggests that individuals who discontinue popular GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who halt traditional diet and exercise regimens.
Research printed in a prominent medical journal demonstrates that while obese individuals frequently drop a large proportion of their body weight while undergoing treatment, the mass comes back at an average rate of nearly a kilo each month upon discontinuation.
"Users purchasing these drugs must be aware of the potential of fast weight regain when the treatment ends," cautioned expert Dr. Susan Jebb.
This pace of regain implies a reversion to original weight within about one and a half years.
Comparing Treatments
The research, which examined dozens of studies involving over 9,000 of patients, compared the effects of GLP-1 agonists with older methods.
Scientists emphasize that individuals who lose weight through lifestyle changes alone usually have a slower weight regain—approximately 100 grams monthly—after stopping.
Explaining the Quick Rebound
Experts believe the mechanism of the drugs explains the heightened rebound.
These medications mimic a body's own chemical called glucagon-like peptide-1, which controls appetite.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production may cause the system to generate a reduced amount of its endogenous hormone, and may also lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication results in hunger is uncontrolled, making binge eating much more probable."
A Lifelong Issue?
The NHS advise the jabs for individuals with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
Professionals say that, due to the high risk of relapse, the treatment is often long-term.
This view is reinforced by pharmaceutical companies, who note that the findings "emphasize the chronic nature of obesity," akin to managing diseases like high blood pressure.
Patient Accounts
Users who have discontinued the medication report a powerful resurgence of hunger.
"It felt as if a trigger flipping and I was suddenly starving," described a patient.
This difficulty is exacerbated if patients have not developed lasting lifestyle or habit modifications during therapy.
Growing Use
Survey data indicate that a significant number of people in the UK have tried these injections in the past year, with desire remaining high.
- Adoption is greater among females compared to males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion obtain the medications through private healthcare rather than the NHS.
In conclusion, clinicians emphasize that while the jabs are effective agents for shedding pounds, they are not a standalone fix and maintained weight loss likely depends on ongoing lifestyle management.
